Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4308-4309
10.1182/blood-2022-156320